Literature DB >> 23206835

Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study.

Zhongwei Jia1, Yurong Mao, Fujie Zhang, Yuhua Ruan, Ye Ma, Jian Li, Wei Guo, Enwu Liu, Zhihui Dou, Yan Zhao, Lu Wang, Qianqian Li, Peiyan Xie, Houlin Tang, Jing Han, Xia Jin, Juan Xu, Ran Xiong, Decai Zhao, Ping Li, Xia Wang, Liyan Wang, Qianqian Qing, Zhengwei Ding, Ray Y Chen, Zhongfu Liu, Yiming Shao.   

Abstract

BACKGROUND: On the basis of the results of the randomised clinical trial HPTN 052 and observational studies, WHO has recommended that antiretroviral therapy be offered to all HIV-infected individuals with uninfected partners of the opposite sex (serodiscordant couples) to reduce the risk of transmission. Whether or not such a public health approach is feasible and the outcomes are sustainable at a large scale and in a developing country setting has not previously been assessed.
METHODS: In this retrospective observational cohort study, we included treated and treatment-naive HIV-positive individuals with HIV-negative partners of the opposite sex who had been added to the national HIV epidemiology and treatment databases between Jan 1, 2003 and Dec 31, 2011. We analysed the annual rate of HIV infection in HIV-negative partners during follow-up, stratified by treatment status of the index partner. Cox proportional hazards analyses were done to examine factors related to HIV transmission.
FINDINGS: Based on data from 38,862 serodiscordant couples, with 101,295·1 person-years of follow-up for the seronegative partners, rates of HIV infection were 2·6 per 100 person-years (95% CI 2·4-2·8) among the 14,805 couples in the treatment-naive cohort (median baseline CD4 count for HIV-positive partners 441 cells per μl [IQR 314-590]) and 1·3 per 100 person-years (1·2-1·3) among the 24,057 couples in the treated cohort (median baseline CD4 count for HIV-positive partners 168 cells per μl [62-269]). We calculated a 26% relative reduction in HIV transmission (adjusted hazard ratio 0·74, 95% CI 0·65-0·84) in the treated cohort. The reduction in transmission was seen across almost all demographic subgroups and was significant in the first year (0·64, 0·54-0·76), and among couples in which the HIV-positive partner had been infected by blood or plasma transfusion (0·76, 0·59-0·99) or heterosexual intercourse (0·69, 0·56-0·84), but not among couples in which the HIV-positive partner was infected by injecting drugs (0·98, 0·71-1·36).
INTERPRETATION: Antiretroviral therapy for HIV-positive individuals in serodiscordant couples reduced HIV transmission across China, which suggests that the treatment-as-prevention approach is a feasible public health prevention strategy on a national scale in a developing country context. The durability and generalisability of such protection, however, needs to be further studied. FUNDING: Chinese Government's 12th Five-Year Plan, the National Natural Science Foundation of China, and the Canadian International Development Research Centre.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23206835     DOI: 10.1016/S0140-6736(12)61898-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  78 in total

1.  The effect of engagement in an HIV/AIDS integrated health programme on plasma HIV-1 RNA suppression among HIV-positive people who use illicit drugs: a marginal structural modelling analysis.

Authors:  L Ti; H Dong; T Kerr; R B Turje; S Parashar; J E Min; J Montaner; E Wood; M-J Milloy
Journal:  HIV Med       Date:  2017-03-19       Impact factor: 3.180

Review 2.  Interventions to improve the HIV continuum of care in China.

Authors:  Xiangjun Zhang; Na Wang; Sten H Vermund; Huachun Zou; Xianhong Li; Fujie Zhang; Han-Zhu Qian
Journal:  Curr HIV/AIDS Rep       Date:  2019-12       Impact factor: 5.071

3.  Economic and public health consequences of delayed access to medical care for migrants living with HIV in France.

Authors:  Marlène Guillon; Michel Celse; Pierre-Yves Geoffard
Journal:  Eur J Health Econ       Date:  2017-03-25

Review 4.  Advances in HIV prevention for serodiscordant couples.

Authors:  Kathryn E Muessig; Myron S Cohen
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

5.  Meeting the Sexual Health Needs of Bisexual Men in the Age of Biomedical HIV Prevention: Gaps and Priorities.

Authors:  Brian A Feinstein; Brian Dodge
Journal:  Arch Sex Behav       Date:  2019-11-05

Review 6.  Toward an endgame: finding and engaging people unaware of their HIV-1 infection in treatment and prevention.

Authors:  David N Burns; Victor DeGruttola; Christopher D Pilcher; Mirjam Kretzschmar; Christopher M Gordon; Elizabeth H Flanagan; Christopher Duncombe; Myron S Cohen
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-11       Impact factor: 2.205

Review 7.  Reaching the unreached: treatment as prevention as a workable strategy to mitigate HIV and its consequences in high-risk groups.

Authors:  Onyema Ogbuagu; R Douglas Bruce
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

Review 8.  Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials.

Authors:  Marie A Brault; Donna Spiegelman; Salim S Abdool Karim; Sten H Vermund
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

9.  Effect of an Electronic Alert on Targeted HIV Testing Among High-Risk Populations.

Authors:  Rulin C Hechter; Zoe Bider-Canfield; William Towner
Journal:  Perm J       Date:  2018

10.  HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States.

Authors:  Raphael J Landovitz; Thuy Tien T Tran; Susan E Cohn; Ighovwhera Ofotokun; Catherine Godfrey; Daniel R Kuritzkes; Jeffrey L Lennox; Judith S Currier; Heather J Ribaudo
Journal:  AIDS Behav       Date:  2016-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.